Microbot Medical Reports Increased Net Loss and Significant Asset Growth in Latest 10-Q Filing

Microbot Medical Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company, which specializes in robotic endoluminal surgery devices, recorded a net loss of $3.5 million for the three months ended June 30, 2025, compared to a loss of $2.5 million in the same period of the previous year. For the six months ended June 30, 2025, the net loss was $6.1 million, up from $4.8 million in 2024. The increase in losses is attributed to higher research and development expenses, which rose to $2.1 million from $1.4 million year-over-year, primarily due to increased outsourcing costs and payroll expenses.

The company’s total assets surged to $33.1 million as of June 30, 2025, compared to $6.0 million at the end of 2024. This increase was driven by a substantial rise in cash and cash equivalents, which reached $4.1 million, and marketable securities, which grew to $28.6 million from $2.4 million. The company’s working capital also improved significantly, increasing to approximately $30.2 million from $3.4 million at the end of the previous fiscal year. This financial boost is largely attributed to successful capital raises, including approximately $32.6 million in gross proceeds from the issuance of common stock and warrants during the first half of 2025.

Operationally, Microbot Medical has made strides in its product development, particularly with its LIBERTY® Endovascular Robotic Surgical System. The company has completed over 100 catheterizations in preclinical studies, achieving a 95% success rate in reaching predetermined vascular targets. The company is currently preparing for a pivotal clinical trial and anticipates submitting an Investigational Device Exemption (IDE) application to the FDA. Additionally, the company has received ISO 13485:2016 certification for its quality management system, which is essential for marketing its products in Europe.

Despite these advancements, Microbot Medical faces ongoing challenges, including the impact of geopolitical tensions in Israel, where its operations are primarily based. The company has noted that while there have been no immediate adverse effects on its business, it continues to monitor the situation closely. Looking ahead, Microbot expects to incur additional losses as it continues its research and development efforts and prepares for commercialization. The company has indicated that it will seek further funding through equity and debt offerings to support its operations and growth initiatives.